Denmark's Coloplast Q2 organic revenue rises 6% on urology momentum

Coloplast A/S

12/05/2026 06:40

Overview

Denmark medical devices maker's Q2 organic revenue grew 6%, reported revenue up 2%

Adjusted EBIT rose 6% in constant currencies, but reported EBIT fell 4% yr/yr

Company took DKK 3 bln Kerecis impairment, resulting in a quarterly net loss

Outlook

Coloplast expects FY 2025/26 organic revenue growth of 5-6%

Company sees FY 2025/26 EBIT growth in constant currencies around 5%

Kerecis is expected to deliver 0% growth due to slower market recovery in out-patient setting

Result Drivers

CHRONIC CARE & INTERVENTIONAL UROLOGY - Strong organic growth in these segments drove overall Q2 performance, with Interventional Urology momentum led by the US Men's Health business

KERECIS DISRUPTION - Kerecis segment saw no growth and a 0% EBIT margin due to significant sales disruption from Medicare reimbursement changes in the out-patient setting, leading to a DKK 3 bln goodwill impairment

CURRENCY HEADWINDS - Reported revenue and EBIT were negatively impacted by currency movements, reducing reported growth by 4 percentage points

Company press release: ID:nGNEc0scmX

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
DKK 7.08 bln
Q2 Net Income
-DKK 971 mln
Q2 Adjusted EBIT
DKK 1.82 bln
Q2 EBIT
-DKK 1.21 bln
Q2 EBIT Margin
-17.00%
Q2 Pretax Profit
-DKK 1.24 bln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 14 "hold" and 5 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Coloplast A/S is DKK480.00, about 19.9% above its May 11 closing price of DKK400.50

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 20 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)